Decreased PBRM1 expression predicts unfavorable prognosis in patients with clear cell renal cell carcinoma

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 8, 2015, Pages 340.e9-340.e16

  Nam, Soo Jeong ^a,b   Lee, Cheol ^a   Park, Jeong Hwan ^a   Moon, Kyung Chul ^a,c  

^a Seoul National University Hospital   (South Korea)

^b National Cancer Center   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

Carcinoma; Immunohistochemistry; Kidney; PBRM1; Prognosis; Renal cell

Indexed keywords

PROTEIN; PROTEIN PBRM1; UNCLASSIFIED DRUG; NUCLEAR PROTEIN; PBRM1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADULT; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; DISEASE SPECIFIC SURVIVAL; FEMALE; FUHRMAN GRADE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEPHRECTOMY; OUTCOME ASSESSMENT; PARTIAL NEPHRECTOMY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TISSUE MICROARRAY; TUMOR VOLUME; DISEASE FREE SURVIVAL; GENETICS; KIDNEY TUMOR; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS;

CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; TRANSCRIPTION FACTORS;

EID: 84937524451     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2015.01.010     Document Type: Article

References (22)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
2. Ferlay J., Shin H.R., Bray F., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
3. Baldewijns M.M., van Vlodrop I.J., Schouten L.J., et al. Genetics and epigenetics of renal cell cancer. Biochim Biophys Acta 2008, 1785:133-155.
4. Latif F., Tory K., Gnarra J., et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science (New York, NY) 1993, 260:1317-1320.
5. Nickerson M.L., Jaeger E., Shi Y., et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 2008, 14:4726-4734.
6. Moore L.E., Nickerson M.L., Brennan P., et al. Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors. PLoS Genet 2011, 7:e1002312.
7. Varela I., Tarpey P., Raine K., et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011, 469:539-542.
8. Reisman D., Glaros S., Thompson E.A. The SWI/SNF complex and cancer. Oncogene 2009, 28:1653-1668.
9. Wilson B.G., Roberts C.W. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 2011, 11:481-492.
10. Shain A.H., Pollack J.R. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PloS One 2013, 8:e55119.
11. Kaelin W.G. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 2004, 10:6290s-6295s.
12. Pena-Llopis S., Vega-Rubin-de-Celis S., Liao A., et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 2012, 44:751-759.
13. Dalgliesh G.L., Furge K., Greenman C., et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010, 463:360-363.
14. Toma M.I., Grosser M., Herr A., et al. Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array. Neoplasia (New York, NY) 2008, 10:634-642.
15. Clifford S.C., Prowse A.H., Affara N.A., et al. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 1998, 22:200-209.
16. Kapur P., Pena-Llopis S., Christie A., et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol 2013, 14:159-167.
17. Xia W., Nagase S., Montia A.G., et al. BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer. Cancer Res 2008, 68:1667-1674.
18. Burrows A.E., Smogorzewska A., Elledge S.J. Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence. Proc Natl Acad Sci U S A 2010, 107:14280-14285.
19. Pawlowski R., Muhl S.M., Sulser T., et al. Loss of PBRM1 expression is associated with renal cell carcinoma progression. Int J Cancer 2013, 132:E11-E17.
20. da Costa W.H., Rezende M., Rocha R.M., et al. PBRM1, a SWI/SNF complex subunit is a prognostic marker in clear cell renal cell carcinoma. BJU Int 2014, 113:E157-163.
21. Hakimi A.A., Chen Y.B., Wren J., et al. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol 2013, 63:848-854.
22. Gossage L., Murtaza M., Slatter A.F., et al. Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma. Genes Chromosomes Cancer 2014, 53:38-51.